Advancing Clinical Trial Design in Chronic Wounds: WCCC Proposes Modernized FDA Guidance
Summary: WoundSource reports on the Wound Care Collaborative Community (WCCC) proposals to modernize FDA guidance for chronic wound trials. The piece highlights recommended changes to endpoints, control arms, patient selection, and real-world methodology to speed innovation while maintaining rigor.
Key Highlights:
- Calls for clinically meaningful endpoints beyond complete closure alone (e.g., durable closure, infection control, pain, function).
- Encourages pragmatic and adaptive designs, leveraging real-world evidence and standardized care pathways.
- Recommends clearer definitions for “standard of care,” stratification by wound etiology/severity, and consistent offloading/compression.
- Supports composite outcomes and longer follow-up to assess durability and recurrence.
Read the full post on WoundSource
Keywords:
WCCC,
FDA guidance,
clinical trial design,
chronic wounds